[Thymogen in the treatment of type-1 diabetes mellitus].
Zhuk. E A EA; Galenok. V A VA
Key Findings
- Thymogen appeared to reverse signs of secondary immunodeficiency in type‑1 diabetes patients.
- Clinical improvements were observed in 94.4% of the treated individuals.
- Laboratory markers of immune function improved in 83.3% of participants.
Practical Outcomes
- For biohackers interested in immune support, thymogen shows promise as an immunomodulatory peptide, especially for autoimmune contexts. However, the study provides limited dosing guidance and is specific to type‑1 diabetes, so broader application requires caution and further research.
Summary
A study gave the peptide thymogen to people with type‑1 diabetes who also had weakened immune systems. Most participants showed clinical improvement (about 94%) and lab markers of immune function improved in about 83%. The authors suggest a dosing schedule, but details are sparse.
Abstract
Thymogen effect was assessed in patients with type 1 diabetes mellitus with clinical and laboratory evidence of secondary immunodeficiency. It was found that thymogen removes signs of secondary immunodeficiency due to activation of T-lymphocyte differentiation. Clinical effect of thymogen was registered in 94.4%, laboratory effect in 83.3% of patients. The scheme of thymogen administration is suggested.
Study Information
pubmed
1996